Related Experiment Videos
Chronic naloxone administration, a potential treatment for migraine, enhances morphine-induced miosis
1Interuniversity Centre of Neurochemistry and Clinical Pharmacology of Idiopathic Headache, Florence, Italy.
Abstract:
The degree and duration of miosis, induced by low doses of parenteral morphine (65 mcg/Kg i.m.) before and after ten days of naloxone treatment, were evaluated in eleven volunteers affected by migraine without aura. Morphine induced miosis was significantly more intense and persistent after chronic naloxone treatment than before the drug was administered. In another group of seven volunteers suffering from migraine without aura, no differences between morphine-induced miosis, prior to and after a ten-day treatment with placebo, were observed. In addition, a third group of fifty-four subjects, suffering from migraine without aura, underwent three-month naloxone treatment (150 mcg/Kg/i.m./day). All subjects included in the third group, were partially or totally refractory to conventional therapy. Pupillopharmacological results indicate that the benefit gained from chronic administration of the opiate antagonist may be related to some type of naloxone-induced supersensitivity of the opioid receptor population.
Insights
Chronic naloxone treatment potentiates morphine-induced miosis in migraine patients, suggesting opioid receptor supersensitivity. This finding offers insights into novel migraine treatment strategies involving opioid system modulation.
Area of Science:
- Neuroscience
- Pharmacology
- Ophthalmology
Background:
- Migraine without aura is a common neurological disorder.
- The role of the endogenous opioid system in migraine pathophysiology is not fully understood.
- Naloxone, an opioid antagonist, has been explored for potential therapeutic benefits in migraine.
Purpose of the Study:
- To investigate the effect of chronic naloxone treatment on morphine-induced miosis in migraineurs.
- To explore the potential mechanism of action for naloxone in migraine treatment.
Main Methods:
- Evaluated miosis (pupil constriction) induced by low-dose parenteral morphine in volunteers with migraine without aura.
- Compared miosis intensity and duration before and after a 10-day course of naloxone treatment.
- Utilized a placebo-controlled group and a longer-term naloxone treatment group (3 months) in subjects refractory to conventional therapy.
Main Results:
- Morphine-induced miosis was significantly more intense and persistent after chronic naloxone treatment compared to baseline.
- No significant changes in morphine-induced miosis were observed after placebo treatment.
- Pupillopharmacological findings suggest naloxone-induced supersensitivity of opioid receptors.
Conclusions:
- Chronic administration of naloxone may enhance opioid receptor sensitivity in individuals with migraine without aura.
- This opioid receptor supersensitivity could explain the therapeutic benefits observed with chronic naloxone treatment in some migraine patients.
- Further research into opioid receptor modulation may reveal new therapeutic avenues for migraine management.